Harmony Biosciences (NASDAQ:HRMY) Downgraded by Wall Street Zen to Hold

Harmony Biosciences (NASDAQ:HRMY) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

HRMY has been the topic of several other research reports. Mizuho set a $50.00 price objective on shares of Harmony Biosciences in a research note on Thursday, February 19th. Truist Financial lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Zacks Research cut Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. UBS Group reduced their price target on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a report on Monday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $42.67.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $28.54 on Friday. The company has a current ratio of 3.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of 10.53, a price-to-earnings-growth ratio of 0.36 and a beta of 0.84. Harmony Biosciences has a twelve month low of $25.52 and a twelve month high of $40.87. The business has a 50 day simple moving average of $36.01 and a 200-day simple moving average of $34.07.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 EPS for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). The business had revenue of $243.78 million during the quarter, compared to analyst estimates of $240.04 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.85 EPS. As a group, equities research analysts expect that Harmony Biosciences will post 2.43 earnings per share for the current year.

Insider Activity at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 25,933 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Sandip Kapadia sold 3,746 shares of the company’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $37.15, for a total value of $139,163.90. Following the sale, the chief financial officer directly owned 24,521 shares of the company’s stock, valued at approximately $910,955.15. This represents a 13.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 50,640 shares of company stock valued at $1,932,256. Company insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Harmony Biosciences

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC grew its stake in Harmony Biosciences by 4,102.4% during the 4th quarter. SG Americas Securities LLC now owns 961,667 shares of the company’s stock valued at $35,986,000 after acquiring an additional 938,783 shares in the last quarter. Boston Partners purchased a new position in shares of Harmony Biosciences during the 2nd quarter valued at $19,398,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Harmony Biosciences by 127.6% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 906,909 shares of the company’s stock worth $28,658,000 after purchasing an additional 508,498 shares in the last quarter. Armistice Capital LLC acquired a new position in shares of Harmony Biosciences during the 4th quarter worth $18,710,000. Finally, AQR Capital Management LLC raised its holdings in shares of Harmony Biosciences by 128.9% during the 4th quarter. AQR Capital Management LLC now owns 813,889 shares of the company’s stock valued at $30,456,000 after purchasing an additional 458,321 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Trending Headlines about Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $55 price target and published a long-range FY2030 EPS projection (which reinforces an upbeat long-term thesis), supporting upside potential despite near-term cuts. HC Wainwright research on HRMY
• Neutral Sentiment: An aggregate coverage note reported HRMY has an average analyst rating of “Moderate Buy,” indicating mixed consensus sentiment across the sell-side. This tempers the impact of individual downgrades but leaves the stock sensitive to further model changes. Average analyst rating report
• Negative Sentiment: Zacks Research downgraded HRMY from “strong-buy” to “hold,” reducing near-term buy-side conviction and likely contributing to selling pressure. Zacks downgrade
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” citing patent trial developments — a direct legal/intellectual property risk that can materially affect exclusivity and future revenue, and is a key reason for today’s weakness. Truist downgrade after patent trial developments
• Negative Sentiment: HC Wainwright also lowered near-term EPS forecasts across Q1–Q4 2026 (multiple cuts to quarterly estimates), signaling weaker near-term profitability expectations that can pressure the stock until guidance or sales trends rebound. HC Wainwright EPS revision details

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.